The acquisition would add to Vertex’s pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Source link
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Date:
More like thisRelated
Iran says Qatar is holding pilots, Israeli strikes kill 11 in Lebanon, and other Middle East news
Iran said Qatar was holding three of its pilots...
Why Buy It When You Can Print It? A DIY Nation Has a Fix for Broken Doodads
Creating replacement parts with 3-D printers can be easier...